135 related articles for article (PubMed ID: 37653610)
41. Two cases of anti-TIF1-γ antibody positive dermatomyositis with manifested symptoms after SARS-CoV-19 vaccination.
Yoshida A; Ikegami T; Igawa K
J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e517-e520. PubMed ID: 35274373
[No Abstract] [Full Text] [Related]
42. A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor.
Varedi D; Frigerio A; Scaife C; Hull C
Dermatol Online J; 2019 Mar; 25(3):. PubMed ID: 30982303
[TBL] [Abstract][Full Text] [Related]
43. Multidisciplinary approach to anti-MDA5 antibody-positive dermatomyositis associated with rapidly progressive interstitial lung disease.
Witkowska AB; Cowley S; Dempsey P; Stack J
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35236677
[TBL] [Abstract][Full Text] [Related]
44. Detection of anti-Mi-2 autoantibodies before dermatomyositis-specific manifestations.
Vulsteke JB; Blockmans D; Moons V; Vijgen S; Bossuyt X; De Langhe E
Rheumatology (Oxford); 2020 Oct; 59(10):e60-e62. PubMed ID: 32118269
[No Abstract] [Full Text] [Related]
45. Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody.
Mizumaki K; Makino S; Ikawa Y; Maeda S; Horii M; Fushida N; Hamaguchi Y; Nohara T; Izumi K; Matsushita T
J Dermatol; 2022 Sep; 49(9):e311-e312. PubMed ID: 35546739
[No Abstract] [Full Text] [Related]
46. Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
Sakurai T; Takahashi J; Komatsu T; Mitsumura H; Iguchi Y
Mod Rheumatol Case Rep; 2023 Jun; 7(2):416-421. PubMed ID: 36715286
[TBL] [Abstract][Full Text] [Related]
47. Clinical and Serological Features and Pregnancy Outcomes in Women with Polymyositis/Dermatomyositis: A Case-based Review.
Ito Y; Yamamoto Y; Suzuki Y; Noda K; Nakajima A
Intern Med; 2022 Jan; 61(2):143-149. PubMed ID: 34334572
[TBL] [Abstract][Full Text] [Related]
48. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
Kotobuki Y; Tonomura K; Fujimoto M
Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
[TBL] [Abstract][Full Text] [Related]
49. A new ELISA for dermatomyositis autoantibodies: rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement.
Muro Y; Sugiura K; Akiyama M
Clin Dev Immunol; 2013; 2013():856815. PubMed ID: 24416061
[TBL] [Abstract][Full Text] [Related]
50. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
51. Dermatomyositis: Muscle Pathology According to Antibody Subtypes.
Tanboon J; Inoue M; Saito Y; Tachimori H; Hayashi S; Noguchi S; Okiyama N; Fujimoto M; Nishino I
Neurology; 2022 Feb; 98(7):e739-e749. PubMed ID: 34873015
[TBL] [Abstract][Full Text] [Related]
52. The clinical spectrum of dermatomyositis and the new autoantibodies - with regard to two clinical cases with distinct associations.
Calvão da Silva JCM; Santiago L; Brites MM; Gonçalo M
Australas J Dermatol; 2020 May; 61(2):e241-e243. PubMed ID: 31881093
[TBL] [Abstract][Full Text] [Related]
53. Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China.
Zhao Y; Su H; Yin X; Hou H; Wang Y; Xu Y; Li X; Zhang N; Sun W; Wei W
Med Clin (Barc); 2023 Jan; 160(1):10-16. PubMed ID: 35842306
[TBL] [Abstract][Full Text] [Related]
54. Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.
Horino T; Inotani S; Nakajima K; Ohnishi H; Komori M; Terada Y
Joint Bone Spine; 2022 Nov; 89(6):105456. PubMed ID: 36108903
[No Abstract] [Full Text] [Related]
55. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
Suga T; Oiwa H; Ishida M; Iwamoto Y
Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
[TBL] [Abstract][Full Text] [Related]
56. Anti-TIF1-γ antibody-positive dermatomyositis caused by camrelizumab in a patient with oesophageal cancer.
Li J; Yi S; Huang Y; Peng Y; Yang Z
Clin Exp Rheumatol; 2023 Mar; 41(2):395. PubMed ID: 36622123
[No Abstract] [Full Text] [Related]
57. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
[No Abstract] [Full Text] [Related]
58. Clinically amyopathic dermatomyositis associated with anti-MDA5 antibody.
Parperis K; Kiyani A
BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29301801
[TBL] [Abstract][Full Text] [Related]
59. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center.
Klein RQ; Teal V; Taylor L; Troxel AB; Werth VP
J Am Acad Dermatol; 2007 Dec; 57(6):937-43. PubMed ID: 17923170
[TBL] [Abstract][Full Text] [Related]
60. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update.
Kobayashi I; Akioka S; Kobayashi N; Iwata N; Takezaki S; Nakaseko H; Sato S; Nishida Y; Nozawa T; Yamasaki Y; Yamazaki K; Arai S; Nishino I; Mori M
Mod Rheumatol; 2020 May; 30(3):411-423. PubMed ID: 31955618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
